Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
Open Access
- 30 December 2009
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2010, 1-7
- https://doi.org/10.1155/2010/740968
Abstract
Ovarian cancer is the fifth leading cause of cancer death in women in North America, and approximately two-thirds of cases of ovarian cancer are of high-grade serous type. The remaining cases are comprised of a mix of different tumor types (e.g., endometrioid, clear cell, mucinous, etc.), with no single tumor type accounting for more than 10% of ovarian cancer cases. These tumor types can be reproducibly diagnosed, and each features distinct underlying molecular events during oncogenesis, with a characteristic natural history and response rate to conventional cytotoxic chemotherapy. In this review the molecular abnormalities present in the more common non-high-grade serous subtypes of ovarian cancer will be presented. Development of targeted therapies for these tumor types will require understanding of the genetic basis of each tumor type, and may lead to subtype-specific therapy.Keywords
This publication has 47 references indexed in Scilit:
- Differences in Tumor Type in Low-stage Versus High-stage Ovarian CarcinomasInternational Journal of Gynecological Pathology, 2010
- Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas—an image cytometric DNA ploidy analysis of 307 cases with histogenetic implicationsVirchows Archiv, 2009
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLoS Medicine, 2008
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesBMC Cancer, 2008
- Synergy between PPARγ Ligands and Platinum-Based Drugs in CancerCancer Cell, 2007
- Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the OvaryObstetrics & Gynecology, 2006
- Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experienceGynecologic Oncology, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian CarcinomaInternational Journal of Gynecological Pathology, 2005
- Activating c-kit Gene Mutations in Human Germ Cell TumorsThe American Journal of Pathology, 1999